

DOCKET NO.: ISIS0052-100 (ISPH-0622)**PATENT****In the Claims:**

The present listing of claims will replace all prior versions and listings of claims in the application.

Please amend claim 1 as follows.

1. (currently amended) An antisense compound 8 to 30 nucleobases in length targeted to the 5' untranslated region, intron/exon junction, intron region, translation termination codon region or 3' untranslated region of a nucleic acid molecule encoding human mdm2 (SEQ ID NO:1), wherein said antisense compound modulates the expression of mdm2 by at least 60%.
2. (original) The antisense compound of claim 1 wherein said antisense compound inhibits the expression of human mdm2.
3. (original) The antisense compound of claim 1 which is an antisense oligonucleotide.
4. (canceled)
5. (previously presented) The antisense compound of claim 2 wherein the nucleic acid molecule encoding mdm2 is the S-mdm2 transcript, and wherein the antisense compound is targeted to the 5' untranslated region of the S-mdm2 transcript.
6. (original) The antisense compound of claim 1 which contains at least one phosphorothioate intersugar linkage.
7. (original) The antisense compound of claim 1 which has at least one 2'-O-methoxyethyl modification.
8. (original) The antisense compound of claim 1 which contains at least one 5-methyl cytidine.

DOCKET NO.: ISIS0052-100 (ISPH-0622)**PATENT**

9. (canceled)

10. (original) A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

11. (original) The pharmaceutical composition of claim 10 wherein said pharmaceutically acceptable carrier or diluent further comprises a lipid or liposome.

12-50. (cancelled)

51. (previously presented) The antisense compound of claim 7 wherein at least one 2'-O-methoxyethyl modification is in a cytidine.

52. (previously presented) The antisense compound of claim 51 in which every 2'-O-methoxyethyl modified cytidine is a 5-methyl cytidine.

53. (previously presented) An antisense compound 8 to 30 nucleobases in length targeted to the coding region or exon region of a nucleic acid molecule encoding mdm2, wherein said antisense compound is a chimeric phosphorothioate oligonucleotide comprising 2'-methoxyethyl wings and a deoxy gap, and wherein said antisense compound inhibits mdm2 expression by at least 60%.

54. (previously presented) The antisense compound of claim 53 wherein said antisense compound inhibits the expression of human mdm2.

55. (previously presented) The antisense compound of claim 53 which comprises at least one 5-methyl cytidine.

DOCKET NO.: ISIS0052-100 (ISPH-0622)**PATENT**

56. (previously presented) The antisense compound of claim 53 wherein at least one 2'-methoxyethyl modification is in a cytidine.

57. (previously presented) The antisense compound of claim 56 in which every 2'-methoxyethyl modified cytidine is a 5-methyl cytidine.

58. (previously presented) A pharmaceutical composition comprising the antisense compound of claim 53 and a pharmaceutically acceptable carrier or diluent.

59. (previously presented) The pharmaceutical composition of claim 58 wherein said pharmaceutically acceptable carrier or diluent further comprises a lipid or liposome.